Novartis Gleevec Drug Interaction Program Is Phase IV For GIST Approval
Executive Summary
Novartis will develop a Gleevec physician-patient drug interaction education program as a Phase IV commitment associated with FDA's approval of the product for treatment of gastrointestinal stromal tumors